泰戈普拉桑与对抗侵蚀性食道炎的质子抑制剂:一种优越的替代品还是另一种选择? 随机对照试验的系统审查和元分析
在PubMed上查看摘要
概括
此摘要是机器生成的。在治愈侵蚀性食道炎 (EE) 方面,Tegoprazan的疗效与质子抑制剂 (PPI) 相当. 然而,泰戈普拉桑与药物相关的不良事件的发生率较高,因此需要进一步评估安全性.
科学领域
- 胃肠病学
- 药理学
- 临床医学
背景情况
- 质子抑制剂 (PPI) 是侵蚀性食道炎 (EE) 的标准药物,但存在长期安全问题.
- 泰戈普拉桑是一种与具有竞争力的酸阻断剂,是EE的潜在替代治疗方法.
研究的目的
- 评估与PPI相比,泰戈普拉桑在EE患者中的疗效和安全性.
- 提供一个随机对照试验的元分析,比较TEGOPRAZAN和PPI用于EE治疗.
主要方法
- 按照PRISMA指南进行系统审查和元分析.
- 包括3项随机对照试验,包括658名EE患者.
- 主要结局: 4 周和 8 周内镜治疗率. 二次结果:不良事件 (AEs),与药物相关的治疗出现的AEs (TEAEs) 和严重的AEs (SAEs).
主要成果
- 与PPI相比,Tegoprazan在4周 (RR1. 05,95%CI0. 96-1.16) 和8周 (RR1. 01,95%CI0. 96-1. 06) 显示出非较低的内观愈合率.
- 在泰戈普拉桑和PPI之间没有发现总体副作用或SAE的显著差异 (RR 1.19,95% CI 0. 92-1.53).
- 与药物相关的TEAE发生率显著增加 (RR 1.23,95% CI 1. 03-1.48).
结论
- 泰戈普拉桑是一种有效的EE治疗方法,其治愈率与PPI相当.
- 虽然整体安全性表现相似,但泰戈普拉桑与更多与药物相关的TEAE有关.
- 需要进一步的长期安全性研究才能广泛采用泰戈普拉桑治疗EE.
相关概念视频
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
In the complex environment of the gastric lumen, excessive acid secretion can lead to the formation or worsening of ulcers within the delicate mucosal layer. Antacids, such as sodium bicarbonate and calcium carbonate, provide relief by neutralizing this acid, transforming it into harmless salt and water. This neutralization process raises the gastric pH from a highly acidic level of 1 to a more basic 3-4, reducing the acidity within the stomach.
However, this neutralization reaction between...

